The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,650.00
Ask: 1,749.00
Change: 0.00 (0.00%)
Spread: 99.00 (6.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS: GlaxoSmithKline Gets Two Downgrades; Prudential Raised

Thu, 04th Feb 2021 09:27

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

----------

FTSE 100

----------

ODDO BHF CUTS GLAXOSMITHKLINE TO 'NEUTRAL' (OUTPERFORM) - PRICE TARGET 1,490 (1,770) PENCE

----------

DEUTSCHE BANK CUTS GLAXOSMITHKLINE TO 'SELL' (HOLD) - PRICE TARGET 1,150 (1,400) PENCE

----------

ODDO BHF RAISES RELX TO 'OUTPERFORM' (NEUTRAL)

----------

JEFFERIES RAISES PRUDENTIAL TO 'BUY' ('HOLD') - PRICE TARGET 1,450 (1,455) PENCE

----------

CREDIT SUISSE RAISES ADMIRAL GROUP TARGET TO 2,290 (1,870) PENCE - 'UNDERPERFORM'

----------

DEUTSCHE BANK RAISES ST JAMES'S PLACE TARGET TO 1,250 (1,160) PENCE - 'HOLD'

----------

CREDIT SUISSE RAISES ASHTEAD GROUP TARGET TO 4,100 (3,775) PENCE - 'OUTPERFORM'

----------

RBC RAISES GLENCORE PRICE TARGET TO 300 (280) PENCE - 'OUTPERFORM'

----------

RBC RAISES GLENCORE PRICE TARGET TO 300 (280) PENCE - 'OUTPERFORM'

----------

BARCLAYS RAISES VODAFONE PRICE TARGET TO 175 (170) PENCE - 'OVERWEIGHT'

----------

GOLDMAN SACHS CUTS RIGHTMOVE PRICE TARGET TO 712 (754) PENCE - 'BUY'

----------

UBS RAISES RIGHTMOVE PRICE TARGET TO 630 (620) PENCE - 'NEUTRAL'

----------

GOLDMAN SACHS CUTS AUTO TRADER GROUP PRICE TARGET TO 679 (688) PENCE - 'BUY'

----------

CREDIT SUISSE RAISES DCC PRICE TARGET TO 6,450 (6,300) PENCE - 'OUTPERFORM'

----------

FTSE 250

----------

UBS RAISES CLOSE BROTHERS PRICE TARGET TO 1400 (995) PENCE - 'NEUTRAL'

----------

UBS RAISES ROYAL MAIL TO 'BUY' ('NEUTRAL') - TARGET 445 (320) PENCE

----------

CREDIT SUISSE RAISES DIRECT LINE TARGET TO 405 (320.77) PENCE - 'OUTPERFORM'

----------

PEEL HUNT RAISES DOMINO'S PIZZA TO 'BUY' ('ADD') - TARGET 425 PENCE

----------

OTHER MAIN MARKET AND AIM

----------

JEFFERIES RAISES NCC GROUP PRICE TARGET TO 292 (245) PENCE - 'BUY'

----------

GOLDMAN RAISES ASOS PRICE TARGET TO 6,500 (5,800) PENCE - 'BUY'

----------

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.